AR061477A1 - Metodos para utilizar un derivado de tiazol - Google Patents

Metodos para utilizar un derivado de tiazol

Info

Publication number
AR061477A1
AR061477A1 ARP070102637A ARP070102637A AR061477A1 AR 061477 A1 AR061477 A1 AR 061477A1 AR P070102637 A ARP070102637 A AR P070102637A AR P070102637 A ARP070102637 A AR P070102637A AR 061477 A1 AR061477 A1 AR 061477A1
Authority
AR
Argentina
Prior art keywords
tetomilast
beta2
receptor agonist
adrenergic receptor
disorder
Prior art date
Application number
ARP070102637A
Other languages
English (en)
Inventor
Kazuhiro Saito
H Nagamoto
N A Molfino
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR061477A1 publication Critical patent/AR061477A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se refiere a un método para tratar una enfermedad, trastorno o afeccion en un paciente que comprende administrar a un paciente una cantidad efectiva para uso terapéutico de un derivado de tiazol, tetomilast. La presente además se refiere a la administracion de al menos un agonista del receptor beta2-adrenérgico con tetomilast para tratar una enfermedad, trastorno o afeccion. Además se refiere a la administracion de un esteroide antiinflamatorio con tetomilast y al menos un agonista del receptor beta2-adrenérgico para tratar una enfermedad, trastorno o afeccion. Reivindicacion 42: Una composicion farmacéutica caracterizada porque comprende tetomilast y al menos un agonista del receptor beta2-adrenérgico. Reivindicacion 46: La composicion farmacéutica de la reivindicacion 45, caracterizada porque el agonista del receptor beta2-adrenérgico se selecciona de salmeterol o albuterol y donde el esteroide antiinflamatorio es fluticasona.
ARP070102637A 2006-06-19 2007-06-15 Metodos para utilizar un derivado de tiazol AR061477A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81454506P 2006-06-19 2006-06-19

Publications (1)

Publication Number Publication Date
AR061477A1 true AR061477A1 (es) 2008-08-27

Family

ID=38514103

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102637A AR061477A1 (es) 2006-06-19 2007-06-15 Metodos para utilizar un derivado de tiazol

Country Status (17)

Country Link
US (1) US20120010179A1 (es)
EP (2) EP2522340A1 (es)
JP (3) JP2009541203A (es)
KR (3) KR20130014645A (es)
CN (2) CN102512676A (es)
AR (1) AR061477A1 (es)
AU (1) AU2007261951B2 (es)
BR (1) BRPI0713388A2 (es)
CA (1) CA2655296A1 (es)
IL (2) IL195894A0 (es)
MX (1) MX2008015380A (es)
PH (1) PH12014501074A1 (es)
RU (1) RU2542502C2 (es)
SG (1) SG184752A1 (es)
TW (2) TWI436761B (es)
WO (1) WO2007148806A1 (es)
ZA (1) ZA200810635B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
KR101360803B1 (ko) 2005-08-15 2014-02-11 베링거 인겔하임 인터내셔날 게엠베하 베타모방제의 제조방법
AU2009224209B2 (en) * 2008-03-14 2015-01-22 Otsuka Pharmaceutical Co., Ltd. MMP-2 and/or MMP-9 inhibitor
TW201542207A (zh) * 2013-10-03 2015-11-16 Otsuka Pharma Co Ltd 嚴重氣喘治療劑

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2829451B2 (ja) 1990-11-30 1998-11-25 大塚製薬株式会社 活性酸素抑制剤
EP0918746B1 (en) * 1996-08-12 2003-04-09 Celgene Corporation Immunotherapeutic agents and their use in the reduction of cytokine levels
MY128323A (en) 1996-09-30 2007-01-31 Otsuka Pharma Co Ltd Thiazole derivatives for inhibition of cytokine production and of cell adhesion
CA2715683A1 (en) * 1999-08-21 2001-03-01 Nycomed Gmbh Synergistic combination
EP1411936B1 (en) * 2001-07-24 2005-09-28 Otsuka Pharmaceutical Co., Ltd. Use of thiazole derivatives for the manufacture of a medicament for the treatment of chronic obstructive pulmonary disease
JP3713577B2 (ja) * 2001-07-24 2005-11-09 大塚製薬株式会社 慢性閉塞性肺疾患治療薬
GB0123951D0 (en) * 2001-10-05 2001-11-28 Glaxo Group Ltd Therapies for treating respiratory diseases
EP1463509A1 (en) * 2001-10-31 2004-10-06 MERCK PATENT GmbH Type 4 phosphodiesterase inhibitors and uses thereof
US20040014563A1 (en) 2002-07-19 2004-01-22 Deere & Company, A Delaware Corporation Transmission shift control with engine torque control
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
AU2005303893A1 (en) * 2004-11-11 2006-05-18 Argenta Discovery Ltd Pyrimidine compounds as histamine modulators
MX2007012084A (es) * 2005-03-30 2007-11-21 Schering Corp Medicamentos y metodos que combinan un anticolinergico, un corticosteroide y un agonista beta de accion prolongada.

Also Published As

Publication number Publication date
IL195894A0 (en) 2009-09-01
WO2007148806A1 (en) 2007-12-27
CN101472570A (zh) 2009-07-01
JP2009541203A (ja) 2009-11-26
AU2007261951B2 (en) 2011-03-31
RU2542502C2 (ru) 2015-02-20
US20120010179A1 (en) 2012-01-12
KR20090021176A (ko) 2009-02-27
BRPI0713388A2 (pt) 2012-03-27
KR20150016344A (ko) 2015-02-11
PH12014501074A1 (en) 2015-09-28
JP2013047281A (ja) 2013-03-07
TWI436761B (zh) 2014-05-11
IL237789A0 (en) 2015-05-31
AU2007261951A1 (en) 2007-12-27
RU2009101317A (ru) 2010-07-27
TW200815054A (en) 2008-04-01
TW201023916A (en) 2010-07-01
SG184752A1 (en) 2012-10-30
CA2655296A1 (en) 2007-12-27
JP2015083596A (ja) 2015-04-30
EP2522340A1 (en) 2012-11-14
MX2008015380A (es) 2008-12-15
KR20130014645A (ko) 2013-02-07
CN102512676A (zh) 2012-06-27
ZA200810635B (en) 2010-03-31
EP2040686A1 (en) 2009-04-01

Similar Documents

Publication Publication Date Title
BRPI0819451A2 (pt) Composição farmacêutica, método para tratar dor, kit farmacêutico, e, uso de uma composição
BRPI1011031A2 (pt) sal de arginina de um agente ativo, composição líquida ou em gel farmaceuticamente aceitável, kit, método para tratamento de uma desordem neurológica e método para tratar ou amenizar a doença de parkinson em um paciente que necessite deste.
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
BRPI0514253A (pt) terapia de combinação para diabetes, obesidade e doenças cardiovasculares usando composições contendo inibidores de gdf-8
BRPI0507189A (pt) uso combinado de um agonista de glp-1 e compostos de gastrina
MX2014002459A (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
BRPI0818687A2 (pt) composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença.
MX2009002921A (es) Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico.
CL2008003582A1 (es) Uso de una composicion farmaceutica que contiene cisteamina o cistamina en la preparacion de un medicamento util para el tratamiento de una enfermedad de higado graso no alcholico (nafld) o esteatohepatitis no alcoholica (nash).
BRPI0514043A (pt) medicamentos para tratar doença respiratória crÈnica
BR112012018500A2 (pt) alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
CL2008000127A1 (es) Compuestos derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, inflamacion, trastornos urologicos
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
BRPI0922789A2 (pt) peptídeo de ligação de albumina intermediador para reconhecimento de doença
PH12017502049A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CR10627A (es) Metodos terapeuticos para el tratamiento de trastornos oculares vasculares con antagonistas de dii4
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
AU2012286851A8 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
AR085662A1 (es) Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia
ATE494889T1 (de) Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol
MX2012006744A (es) Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas.
AR061477A1 (es) Metodos para utilizar un derivado de tiazol
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
BRPI1015539A2 (pt) composições e métodos para tratamento de queimaduras
CL2012001349A1 (es) Uso de una composicion farmaceutica que comprende telmisartan para el tratamiento de hipertension sistemica en gatos ( div. sol. 2897-07).

Legal Events

Date Code Title Description
FB Suspension of granting procedure